

# FDA-APPROVED BREAST CANCER TREATMENTS

Generic	Brand	Strength	Form	Usual Dose
<b>Alkylating Agents</b>				
cyclophosphamide	—	25mg, 50mg	tabs	1–5mg/kg/day
	<b>Cytoxan injection</b>	500mg, 1g, 2g	pwd for IV inj after reconstitution	40–50mg/kg in divided doses over 2–5 days or 10–15mg/kg every 7–10 days or 3–5mg/kg twice weekly
thiotepa	—	15mg	pwd for IV, intravesical, or intracavitary admin after reconstitution	0.3–0.4mg/kg IV once every 1–4wks
<b>Antibiotics (Cytotoxic)</b>				
doxorubicin	—	10mg, 20mg, 50mg, 2mg/mL	pwd for IV inj after reconstitution soln for IV inj	<i>Monotherapy:</i> 60–75mg/m <sup>2</sup> every 21 days <i>Combination therapy:</i> 40–60mg/m <sup>2</sup> every 21–28 days
epirubicin	<b>Ellence</b>	2mg/mL	soln for IV infusion	100–120mg/m <sup>2</sup> on Day 1 or divided equally given on Days 1 and 8 of each cycle
<b>Antiestrogen</b>				
tamoxifen	<b>Soltamox Oral Solution</b>	10mg/5mL	oral soln	20–40mg/day
—	—	10mg, 20mg	tabs	—
toremifene	<b>Fareston</b>	60mg	tabs	60mg once daily
<b>Antimetabolites</b>				
capecitabine	<b>Xeloda</b>	150mg, 500mg	tabs	<i>Monotherapy:</i> 1250mg/m <sup>2</sup> twice daily <i>Combination therapy:</i> Give with docetaxel 75mg/m <sup>2</sup> IV infused over 1hr every 3wks
flourouracil	—	50mg/mL	soln for IV inj	12mg/kg once daily for 4 successive days; max 800mg/day
gemcitabine	<b>Gemzar</b>	200mg, 1g	pwd for IV infusion after reconstitution	1250mg/m <sup>2</sup> on Days 1 and 8 of each 21-day cycle
methotrexate	—	25mg/mL	soln for IV, IM, intra-arterial, or intrathecal admin after dilution	See drug entry and manufacturer's literature
	—	1g	pwd for IV, IM, intra-arterial, or intrathecal admin after dilution	
	<b>Trexall</b>	5mg, 7.5mg, 10mg, 15mg	scored tabs	
<b>Antimicrotubule agents</b>				
docetaxel	<b>Taxotere</b>	40mg/mL	soln for IV infusion after dilution	60–100mg/m <sup>2</sup> once every 3wks
eribulin mesylate	<b>Halaven</b>	0.5mg/mL	soln for IV inj	1.4mg/m <sup>2</sup> IV inj over 2–5min on Days 1 and 8 of each 21-day cycle
ixabepilone	<b>Ixempra</b>	15mg, 45mg	pwd for IV infusion after constitution and dilution	40mg/m <sup>2</sup> once every 3wks
paclitaxel	<b>Abraxane</b>	100mg	IV infusion; inj susp after reconstitution	260mg/m <sup>2</sup> every 3wks
	<b>Taxol</b>	6mg/mL	soln for IV infusion after dilution	175mg/m <sup>2</sup> every 3wks
vinblastine	—	10mg	lyophilized pwd for IV inj or infusion after reconstitution	5.5–7.4mg/m <sup>2</sup> once weekly (see literature)
	—	1mg/mL	soln for IV inj or infusion	
<b>Aromatase Inhibitor</b>				
anastrozole	<b>Arimidex</b>	1mg	tabs	1mg once daily
exemestane	<b>Aromasin</b>	25mg	tabs	25mg once daily
letrozole	<b>Femara</b>	2.5mg	tabs	2.5mg once daily
<b>Estrogen</b>				
estradiol	<b>Estrace</b>	0.5mg, 1mg, 2mg	scored tabs	10mg 3 times daily for at least 3mos
<b>Estrogen Receptor Antagonist</b>				
fulvestrant	<b>Faslodex</b>	50mg/mL	soln for IM inj	500mg on days 1, 15, 29, then once monthly thereafter
<b>GnRH Analogue</b>				
goserelin	<b>Zoladex</b>	3.6mg	SC implant	One 3.6mg implant every 28 days
<b>Human Epidermal Growth Factor Receptor (HER2) Inhibitor</b>				
pertuzumab	<b>Perjeta</b>	420mg/14mL (30mg/mL)	soln for IV infusion	Initially 840mg IV over 60min, followed every 3wks thereafter by a dose of 420mg IV over 30–60min in combination with trastuzumab and docetaxel. <i>Dose modification (missed dose, LVEF, or infusion reactions):</i> See literature.
trastuzumab	<b>Herceptin</b>	440mg	lyophilized pwd for IV infusion after reconstitution and dilution	See drug entry
<b>mTOR Kinase Inhibitor</b>				
everolimus	<b>Afinitor</b>	2.5mg, 5mg, 7.5mg, 10mg	tabs	10mg once daily
<b>Progestin</b>				
megestrol acetate	—	20mg, 40mg	scored tabs	40mg 4 times daily
<b>Selective Estrogen Receptor Modulator (SERM)</b>				
raloxifene	<b>Evista</b>	60mg	tabs	60mg once daily
<b>Tyrosine Kinase Inhibitor</b>				
lapatinib	<b>Tykerb</b>	250mg	tabs	See drug entry and manufacturer's literature

## NOTES

Not an inclusive list of medications and/or doses. Please see drug monograph at [www.eMPR.com](http://www.eMPR.com) and/or contact company for full drug labeling.